Nachrichten zur Arena Pharmaceuticals Inc. Aktie

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…

Have $500? 2 High-Yield Dividend Stocks to Buy Right Now

Dividend stocks can be a great way to boost your portfolios growth potential or provide a form of passive income…

Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical…

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

…

Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript

…

Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda

Cycle Pharmaceuticals Ltd. is still interested in acquiring Vanda Pharmaceuticals Inc. after one of Vanda’s drugs failed to receive regulatory…

Deep Track Capitals Strategic Investment in Reneo Pharmaceuticals

On October 4, 2024, Deep Track Capital, LP (Trades, Portfolio) marked a significant portfolio addition by acquiring 68,415.6 shares of…

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

…

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript

…

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged…

Pfizer: AbbVie, Bristol-Myers, Eli Lilly, Johnson & Johnson, Takeda - Die Konkurrenz ist enorm - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Pfizer-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Pfizer Inc. (ISIN: US7170811035,…

Pfizer: Enorme Konkurrenz

Mitte Dezember 2021 hat Pfizer die milliardenschwere Übernahme von Arena Pharmaceuticals verkündet und sich somit den Zugriff auf die Substanz…

Pfizer: Enorme Konkurrenz

Mitte Dezember 2021 hat Pfizer die milliardenschwere Übernahme von Arena Pharmaceuticals verkündet und sich somit den Zugriff auf die Substanz…

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

…

dpa-AFX ProFeed